Indian pharmaceutical stocks came under significant selling pressure on Wednesday after US President Donald Trump proposed a phased tariff plan that could impose duties of up to 200% on imported generic medicines over the next three years
The Indian rupee weakened against the US dollar in early trade on Wednesday as escalating geopolitical tensions in the Middle East pushed crude oil prices to multi-week highs.
Bandhan Bank Ltd. came under intense selling pressure on Wednesday after reporting a mixed set of first-quarter FY27 results and significantly lowering its profitability guidance for the current financial year.
Global crude oil prices climbed sharply on Wednesday, with Brent crude rising above $92 per barrel for the first time in more than a month.
Indian equity markets witnessed a sharp correction on Wednesday as a combination of rising crude oil prices, renewed geopolitical tensions in the Middle East.
While the quarterly numbers are expected to remain healthy, investors will primarily focus on management's outlook for FY27, the large deal pipeline, artificial intelligence (AI) opportunities and trends in discretionary technology spending.
Launched to encourage tourism, strengthen the hospitality industry and create more lively public spaces, the policy was expected to simplify approvals and promote a modern urban dining culture.
The stock has now rallied around 12% over the past three trading sessions and recovered nearly 34% from its June 2026 low, reflecting renewed investor confidence in one of India's leading specialty chemical manufacturers.
The development not only expands Emcure's specialty medicine portfolio but also opens up a new growth opportunity in one of the fastest-growing segments of metabolic healthcare